According to Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine has received a two-year $795,000 grant from the Alzheimer’s Association to support a Phase 2 trial of empagliflozin and intranasal insulin for Alzheimer’s disease. The trial will be led by Wake Forest professor Suzanne Craft, who is director of the Alzheimer’s Disease Research Center at the School of Medicine.
The 4-week clinical trial supported by the grant will evaluate intranasal insulin alone against empagliflozin alone, intranasal insulin plus empagliflozin, and placebo. Craft explained , “We know Type 2 diabetes has been linked to an increased risk of dementia. Many patients with Alzheimer’s disease also have insulin resistance.”
Read the Wake Forest press release.
